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Research
Research on the environmental fate and toxi-
cology of halogenated compounds has focused 
primarily on brominated and chlorinated 
organics, whereas fluorinated organics received 
less attention, partly because of the percep-
tion that these compounds, which are quite 
chemically inert, were also biologically inert 
(Key et al. 1997). However, perfluorinated 
fatty acids (PFFAs), such as perfluorooctano-
ate (PFOA) and perfluoro  octane sulfonate 
(PFOS), are found in the environment and 
have been detected in the blood of animals 
throughout the world, including the seals of 
remote arctic regions, indicating widespread 
distribution (Kannan 2001; Tao 2006; Van 
de Vijver 2005). Significant levels of PFOA 
and PFOS have also been detected in the 
serum of humans, but there is evidence of 
a significant decline in body burdens of 
PFOS and PFOA over the last 5–10 years 
(Calafat et al. 2007). The values from the first 
National Health and Nutrition Examination 
Survey (NHANES) conducted from 1999 to 
2000 reported geometric means of 30.4 µg 
PFOS/L and 5.4 µg PFOA/L, and the sec-
ond NHANES conducted between 2003 and 
2004 reported geometric means of 20.7 µg 
PFOS/L and 3.9 µg PFOA/L (Calafat et al. 
2007). Contamination of the environment 
is not limited to PFOA and PFOS but also 
includes short-chain perfluorinated alkano-
ates, such as perfluorobutyrate, perfluoro-
pentanoate (PFPeA), perfluorohexanoate, and 
perfluoroheptanoate (Skutlarek et al. 2006).
The acute toxicities of PFOA and 
PFOS in rodent systems are low (Hekster 
2003; Kudo and Kawashima 2003). After 
the absorption of PFOA into the body, it is 
predominantly distributed in the liver and 
plasma and, to a lesser extent, the kidney and 
lungs (Kudo and Kawashima 2003). Thus, 
the chronic and short-term effects of PFOA 
in rats are found largely in the liver (Kennedy 
et al. 2004) and immune system (DeWitt 
et al. 2008). Peroxisome proliferation in 
rodent livers is one of the major responses 
to PFOA, along with subsequent interfer-
ences with normal metabolism of fatty acids 
and cholesterol, and the induction of hepa-
tocellular hypertrophy (Kennedy et al. 2004). 
Peroxisome-proliferating chemicals are clas-
sic nongenotoxic tumor promoters in rodent 
liver tissue (Cattley et al. 1995), and like other 
peroxisome proliferators, PFOA has also been 
shown to strongly promote tumors in rodent 
livers (Abdellatif et al. 1991). However, 
peroxisome-proliferating compounds might 
not be strong tumor promoters in human 
livers because of species differences in the 
response to peroxisome proliferators in vivo, 
with rodents more responsive than primates 
(Klaunig et al. 2003).
Although the underlying mechanisms of 
tumor promotion might vary, such as the 
induction of peroxisome proliferation, tum-
origenic cells have long been characterized as 
cells that lose their ability to regulate growth 
through contact inhibition (Borek and Sachs 
1966) and lack the ability to terminally dif-
ferentiate (Potter 1978), which implies a 
breakdown in one of the communicating 
mechanisms (Trosko and Upham 2005). 
Tumorigenic cells can be benign, leading to 
the compression of surrounding tissues, or 
have the potential to acquire genetic muta-
tions that lead to a malignant state where the 
cancerous cells can invade surrounding tis-
sues. Alteration of cell-to-cell communication 
via gap junctions has been implicated in the 
tumorigenic process and is supported by con-
siderable evidence (Trosko and Ruch 2002).
Inhibition of gap-junctional intercellular 
communication (GJIC) appears to be a neces-
sary, albeit insufficient, step of tumorigenesis 
and is therefore a common response of cells to 
tumor promoters, oncogenes, growth factors, 
and nongenotoxic carcinogens such as peroxi-
some proliferators (Trosko and Ruch 1998; 
Trosko and Upham 2005). Although GJIC 
is modulated by multiple signaling pathways, 
simple bioassays of intercellular communica-
tion can be used to assess dysregulation of gap 
junctions regardless of the upstream effectors. 
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Ba c k g r o u n d: Perfluoroalkanoates, [e.g., perfluorooctanoate (PFOA)], are known peroxisome 
  proliferators that induce hepatomegaly and hepatocarcinogenesis in rodents, and are classic non-
genotoxic carcinogens that inhibit in vitro gap-junctional intercellular communication (GJIC). This 
inhibition of GJIC is known to be a function of perfluorinated carbon lengths ranging from 7 to 10.
oB j e c t i v e s: The aim of this study was to determine if the inhibition of GJIC by PFOA but not 
perfluoropentanoate (PFPeA) observed in F344 rat liver cells in vitro also occurs in F344 rats in vivo 
and to determine mechanisms of PFOA dysregulation of GJIC using in vitro assay systems.
Me t h o d s : We used an incision load/dye transfer technique to assess GJIC in livers of rats exposed to 
PFOA and PFPeA. We used in vitro assays with inhibitors of cell signaling enzymes and antioxidants 
known to regulate GJIC to identify which enzymes regulated PFOA-induced inhibition of GJIC.
re s u l t s: PFOA inhibited GJIC and induced hepatomegaly in rat livers, whereas PFPeA had no 
effect on either end point. Serum biochemistry of liver enzymes indicated no cytotoxic response 
to these compounds. In vitro analysis of mitogen-activated protein kinase (MAPK) indicated that 
PFOA, but not PFPeA, can activate the extracellular receptor kinase (ERK). Inhibition of GJIC, 
in vitro, by PFOA depended on the activation of both ERK and phosphatidylcholine-specific phos-
pholipase C (PC-PLC) in the dysregulation of GJIC in an oxidative-dependent mechanism.
co n c l u s i o n s: The in vitro analysis of GJIC, an epigenetic marker of tumor promoters, can also 
predict the in vivo activity of PFOA, which dysregulated GJIC via ERK and PC-PLC.
key w o r d s : extracellular receptor kinase, gap-junctional intercellular communication, mitogen-
activated protein kinase, perfluorooctanoate, perfluoropentanoate, phosphatidylcholine-specific-
phospholipase C, tumor promotion. Environ Health Perspect 117:545–551 (2009).  doi:10.1289/
ehp.11728 available via http://dx.doi.org/ [Online 23 October 2008]Upham et al.
546  v o l u m e  117 | n u m b e r  4 | April 2009  •  Environmental Health Perspectives
Thus, GJIC is an excellent biomarker first to 
assess the potential tumorigenicity of chemi-
cals and then to use as a cell signaling end 
point to determine the early molecular events 
induced by these chemicals.
Cell proliferative diseases, such as cancer, 
not only require the release of a quiescent cell 
from growth suppression via down-  regulation 
of GJIC and/or changes in extracellular com-
ponents (i.e., integrins), but also need to 
activate mitogenic signaling pathways. The 
mitogen-activated protein kinase (MAPK) 
pathways are the major intracellular signal-
ing mechanisms by which a cell activates, via 
phosphorylation, transcription factors involved 
in mitogenesis (Denhardt 1996). The extracel-
lular receptor kinase (ERK) pathway has been 
extensively characterized, is the most under-
stood of the MAPK pathways (Denhardt 
1996), and is a key pathway of carcinogenesis 
(Roberts and Der 2007).
In the present study, we extended our 
in vitro studies with F344 rat liver epithelial 
cells, which determined that PFOA, but not 
PFPeA, inhibited GJIC (Upham et al. 1998), 
to an in vivo study using F344 rats exposed 
to PFOA, PFPeA, or phenobarbital (PB), a 
known tumor promoter, to determine GJIC 
in liver tissue. We also continued our in vitro 
studies of PFOA versus PFPeA in determin-
ing differential effects of these compounds on 
MAPK, specifically ERK, and further deter-
mined that the mechanism of PFOA-induced 
inhibition of GJIC depends on redox activity, 
ERK, and phosphatidylcholine-specific phos-
pholipase C (PC-PLC).
Materials and Methods
Chemicals. We purchased PFOA (purity 
> 90%) and PFPeA (purity = 97%), for the 
data presented in Figures 1–3 and 4A, from 
Fluka Chemie AG (Buchs, Switzerland), 
and because of unavailability from Fluka, we 
purchased PFOA for the data presented in 
Figures 4B, 5, and 6 from Aldrich Chemical 
Company Inc. (Milwaukee, WI, USA), with 
a purity of 96%. The purity values were 
obtained from the commercial sources. The 
ratios of linear versus branched isomers in our 
samples were undetermined. The stock solu-
tions were prepared by dissolving the pow-
der in the solvent: acetonitrile for the in vitro 
assays and dimethyl sulfoxide (DMSO) for 
the in vivo studies; we also used these sol-
vents as the vehicle controls. We purchased 
Lucifer yellow (LY) from Molecular Probes 
(Eugene, OR, USA); sodium dodecyl sul-
fate, Tween 20, Tris, glycine, acrylamide, 
tetramethylethylenediamine (TEMED) and 
DC protein kit from Bio-Rad Laboratories 
(Hercules, CA, USA); DMSO, rhodamine-
dextran (RhD; molecular weight, 10,000 
Da), dithiothreitol (DTT), N-acetylcysteine 
(Nac), l-ascorbate-2-phosphate (Asc-2-P) 
sesquimagnesium salt hydrate, and PB from 
Sigma-Aldrich Chemical Company (St. Louis, 
MO, USA); D609 and U0126, from Tocris 
Bioscience (Ellisville, MO, USA); resvera-
trol from CTMedChem (Bronx, NY, USA); 
acetonitrile, from EM Science (Gibstown, 
NJ, USA); polyclonal antibodies directed to 
phospho-ERK, from New England Biolabs 
(Ipswich, MA, USA); and mouse poly-
clonal antibody directed to glyceraldehyde 
3-phosphate dehydrogenase (GAPDH), from 
Chemicon (Temecula, CA, USA).
In vivo study. Animal treatment. The 
protocol for this study was approved by the 
Animal Care and Utilization Committee of 
the National Institutes of Health Sciences 
of Japan to assure that the rats were treated 
humanely and with regard for alleviation 
of suffering. Male Fischer-344 (F344) rats, 
5 weeks old, were purchased from Charles 
River Japan (Kanagawa, Japan) and housed in 
plastic cages (five rats/cage). Male F-344 rats 
were chosen to match the in vitro studies that 
used liver epithelial cells isolated from male 
F-344 rats. The rats were kept under condi-
tions of controlled temperature (23 ± 2°C), 
humidity (55 ± 5%), and lighting (12/12-hr 
dark/light cycle) and given CRF-12 basal diet 
(Oriental Yeast Co., Tokyo, Japan) and tap 
water ad libitum. 
We used the rats in the experiments after 
1 week of acclimation. Eighty rats were divided 
into four groups and twenty rats per group 
were treated with a single intraperitoneal (i.p.) 
administration of 100 mg/kg PFOA, 100 mg/
kg PFPeA, 100 mg/kg PB, or only vehicle 
(DMSO). Four rats per group were killed 
under anesthesia at 1, 3, 6, 12, and 24 hr after 
administration. Another 16 rats were divided 
into four groups and four rats of each group 
were given powder diet containing PFOA, 
PFPeA, PB, or basal powder diet only (con-
trol), and then killed after 1 week. The diets 
were prepared by blending each chemical into 
the basal powder diet at final concentrations 
of 0.02% for PFOA and PFPeA and 0.05% 
for PB. We determined the weight of the rats 
at the beginning and end of the experiment, 
and the food consumption on days 3 and 7 of 
the experiment. Based on the average weight 
of the rats and the average food consumed 
per day, the estimated daily doses of chemical 
exposures for PFOA, PFPeA, and PB were 
37.9, 32.3, and 93.3 mg/day/kg, respectively. 
Diethyl ether was used to euthanize the 
rats. Before sacrifice, blood was collected from 
the orbital venous plexus under anesthesia with 
diethyl ether and prepared for measuring serum 
aspartate aminotransferase (sAST), serum ala-
nine aminotransferase (sALT), and serum alka-
line phosphatase (sALP). Determination of 
sAST, sALT, and sALP was carried out with 
a Hitachi automatic Analyzer 7150 (Hitachi, 
Ltd., Tokyo, Japan) using commercially avail-
able GOP, GPT and ALP diagnostic reagents 
(Wako Pure Chemical Industries, Ltd., Tokyo, 
Japan). After opening the abdominal cavity, we 
excised the liver and immediately used one part 
of the liver for the incision loading/dye transfer 
(IL/DT). Our preliminary study confirmed 
that the anesthetic and the vehicle, DMSO, 
under our experimental conditions did not 
affect in vivo GJIC.
Bioassay of GJIC (IL/DT). We assayed 
ex vivo GJIC in the liver by the IL/DT method 
described previously (Sai et al. 2000). A part 
of the left lobe of the liver was put on a plastic 
Figure 1. Analysis of in vivo effects of PFOA and PFPeA on GJIC in the liver tissue using IL/DT technique. Abbreviations: 5-C, five carbon; 8-C, eight carbon. 
(A) A fluorescent image of an IL/DT analysis of GJIC in the liver tissue of rats at 24 hr after a single i.p. administration of DMSO (vehicle), PB, PFOA, or PFPeA. 
Bar = 20 µm. (B) Mean + SD of the IL/DT data from rats treated with DMSO, PB, PFOA, or PFPeA for the acute exposure group. (C) Mean + SD relative liver weight 
from rats treated with DMSO, PB, PFOA, and PFPeA for the acute exposure group. 
*p < 0.05 compared with vehicle, determined by one-way ANOVA for each time group followed by Dunnett’s post hoc test.
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plate covered with wet gauze. A mixture of 
fluorescent dyes containing 0.5 mg/mL LY 
and 0.5 mg/mL RhD in phosphate-buffered 
saline (PBS) was dropped on the tissue’s sur-
face. Three to four incisions were made on the 
surface of each specimen with a sharp blade. 
Excess amount of dye mixture was addition-
ally put into the incisions and kept there for 
3 min at room temperature. After incubation, 
the tissue was washed with PBS three times 
and fixed in 10% phosphate-buffered formalin 
overnight. Slices were washed with water and 
processed for embedding in paraffin. Five µm 
sections for GJIC analysis were prepared by 
cutting the paraffin block perpendicular to 
the incision line. Areas stained with LY alone 
or with RhD were detected by the emission 
of fluorescence using a confocal microscope 
(Fluoview, Olympus, Tokyo, Japan). We 
counted the number of cells stained with LY 
alone and normalized this number by divid-
ing by the incision length. At least three inci-
sion sites per specimen were randomly chosen 
for the analysis, and the mean value was used 
as data from one animal. The values were 
expressed as a fraction of the control.
In vitro study. Cell culture. We obtained 
the WB-F344 rat liver epithelial cell line from 
J.W. Grisham and M.S. Tsao of the University 
of North Carolina at Chapel Hill, Chapel 
Hill, NC, USA (Tsao et al. 1984). Cells were 
cultured in D-medium (formula 78-5470EF, 
Gibco Laboratories, Grand Island, NY, USA), 
supplemented with 5% fetal bovine serum 
(Gibco Laboratories), and incubated at 37°C 
in a humidified atmosphere containing 5% 
CO2 and 95% air. The cells were grown in 
35-mm tissue culture plates (Corning Inc., 
Corning, NY, USA) and the culture medium 
was changed every other day. Bioassays were 
conducted with confluent cultures that were 
obtained after 2–3 days of growth.
These WB cells are diploid and nontu-
morigenic (Tsao et al. 1984) and have been 
extensively characterized for GJIC in the 
absence and presence of well-known tumor 
promoters, growth factors, tumor suppres-
sor genes, and oncogenes (Trosko and Ruch 
1998). Intrahepatic transplantation of WB 
cells, which are liver bipolar stem cells, into 
adult syngenic F344 rats results in the mor-
phologic differentiation of these cells into 
hepatocytes and incorporation into hepatic 
plates (Coleman et al. 1993).
Bioassay of GJIC (scrape load/dye trans-
fer). The scrape loading/dye transfer (SL/DT) 
technique was adapted after the method of 
Upham et al. (1998). The test chemicals were 
added directly to the cell culture medium 
from concentrated stock solutions. The 
migration of the dye through gap junctions 
was visualized with a Nikon Eclipse TE3000 
phase contrast/fluorescent microscope and the 
images were digitally captured with Nikon 
EZ Cool Snap charge-coupled device cam-
era (Nikon Inc., Nikon, Japan). GJIC was 
assessed by comparing the distance the dye 
traveled in the chemically treated cells with 
the distance the dye traveled in the vehicle 
controls, which was measured using the Gel-
Expert imaging software (Nucleotech, San 
Mateo, CA, USA). We report GJIC as a frac-
tion of the control. Based on previous results 
(Upham et al. 1996, 1998), 1-methylanthra-
cene as well as PFOA were used as positive 
controls of inhibition of GJIC, whereas ace-
tonitrile at vehicle concentrations was used as 
a negative control. The vehicles used for the 
in vitro assays, acetonitrile and PBS, had no 
effect on GJIC. We performed all experiments 
at least in triplicate and report the results as 
means ± SD at the 95% confidence interval.
Western blot analysis. Cells were grown 
in 35-mm-diameter Corning tissue culture 
plates to the same confluency as the SL/DT 
assay. The cells were depleted of serum 5 hr 
before addition of PFFAs to synchronize the 
cells into G0 to minimize background ERK 
levels. This does not alter the effect on GJIC 
in the F344 WB cells, as previously deter-
mined (Rummel et al. 1999). The proteins 
were extracted with 20% sodium dodecyl sul-
fate (SDS) solution containing 1 mM phenyl-
methylsulfonyl fluoride, 100 µM Na3VO4, 
100 nM aprotinin, 1.0 µM leupeptin, 1.0 µM 
antipain, and 5.0 mM NaF. The protein 
content was determined with the Bio-Rad 
DC assay kit. The proteins were separated on 
12.5% SDS–polyacrylamide gel electropho-
resis according to the method of Laemmli 
Figure 2. The long-term effects (1 week) of PB, 
PFOA, and PFPeA on GJIC and RLW (mean + SD). 
Abbreviations: 5-C, five carbon; 8-C, eight carbon. 
A one-way ANOVA was done for the GJIC data 
and a Kruskal-Wallis one-way ANOVA was done 
for the RLW data because these data failed the 
normality test. 
*p < 0.05 compared with vehicle (DMSO); significant 
effects determined by ANOVA or Kruskal-Wallis ANOVA 
for each group was followed with a Dunnett’s post hoc 
test at p < 0.05. 
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Figure 3. Activation of ERK-MAPK by PFOA, but not by PFPeA, in F344 WB rat liver epithelial cells deter-
mined by Western blots: Top panel probed with a phosphorylated ERK specific antibody and the bottom 
panel probed with a GAPDH specific antibody. The concentrations of PFPeA and PFOA were 100 µM. The 
concentration and time of incubation for epidermal growth factor (EGF) was 20.0 ng/mL and 15 min.
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Figure 4. (A) Prevention of PFOA-induced inhibition of GJIC by inhibitors of MEK and PC-PLC and resvera-
trol at various doses of PFOA (mean + SD). The concentrations and times of preincubation of U0126, D609, 
and resveratrol were 20 µM/30 min, 50 µM/20 min, and 100 µM/15 min, respectively. A one-way ANOVA 
was done for each dose group. *Significant at p < 0.05 using the Dunnett’s post hoc test that compared 
each inhibitor treatment with that of PFOA alone. (B) The interactive effect of MEK and PC-PLC inhibitors 
on reversing PFOA-induced inhibition of GJIC at 10 and 30 min (mean + SD). The concentrations and times 
of preincubation of U0126 and D609 were 20 µM/30 min and 50 µM/20 min, respectively. A one-way ANOVA 
indicated significance at p < 0.05 for each time group. The Tukey pairwise-comparison post hoc test was 
used to determine statistical differences, as indicated by different letters, between the inhibitor treatments 
for each time group. The lettered asterisks represent the 10-min group and lettered daggers represent the 
30-min group.
1.00
0.75
0.50
0.25
0.00
G
J
I
C
(
f
r
a
c
t
i
o
n
 
o
f
 
t
h
e
 
c
o
n
t
r
o
l
)
120
* A B PFOA  alone
+ U0126
+ D609
+ Resveratrol
PFOA dose (µM)
100 80 60 40 20
*
*
*
*
*
*
*
1.25
1.00
0.75
0.50
0.25
0.00
G
J
I
C
(
f
r
a
c
t
i
o
n
 
o
f
 
t
h
e
 
c
o
n
t
r
o
l
)
None D609 U0126 D609 +
U0126
a*
a†
b*
a,b†
b*
b†
c*
c†
10 min PFOA
30 min PFOAUpham et al.
548  v o l u m e  117 | n u m b e r  4 | April 2009  •  Environmental Health Perspectives
(1970). Fifteen micrograms protein was 
loaded onto the gels and electrophoretically 
transferred from the gel to polyvinyl difluo-
ride membranes (Millipore Corp., Bedford, 
MA, USA). Phosphorylated ERK 1 and 
ERK 2 were detected with a 1:2,000 dilu-
tion of anti-phospho-ERK polyclonal anti-
bodies, and GAPDH was detected with a 
1:10,000 dilution of anti-GAPDH polyclonal 
antibodies, that were incubated sequen-
tially with the membranes, each for 2 hr. 
The protein–primary antibody complex was 
probed with a 1:1,000 dilution of horseradish 
peroxidase–conjugated anti-rabbit or anti-
mouse antibodies (Amersham Life Science 
Products, Arlington Heights, IL, USA) for 
1 hr. The ERK and GAPDH protein bands 
were detected using the Super Signal chemi-
luminescence detection kit (Pierce Corp., 
Arlington Heights, IL, USA), enhanced 
chemiluminescence (ECL) detection kit, and 
ECL Hyperfilm–MP (Amersham Life Science 
Products, Denver, CO, USA).
Statistics. For the in vivo studies, the value 
of each group was expressed as the mean ± SD 
of data derived from four rats. The in vitro 
assays were done in at least triplicate and 
expressed as a fraction of the control. The sig-
nificance of differences in all results was evalu-
ated with either a one-way analysis of variance 
(ANOVA) or, if the data set failed the normal-
ity test, a Kruskal-Wallis one-way ANOVA on 
ranked means. Normality assumption testing 
was done with the Kolmogorov-Smirnov test 
and equal variance assumption testing with the 
Levene median test. If ANOVA or Kruskal-
Wallis ANOVA rejected the null hypothesis, 
then the results that were compared with a 
designated control used Dunnett’s multiple-
comparison post hoc tests or Tukey’s post hoc 
test for pairwise multiple comparisons.
Results
In vivo results. The in vivo results of PFOA 
and PFPeA were compared with PB, a known 
liver tumor promoter. We used two different 
dosing schemes: an acute 24-hr exposure via 
i.p. administration and a longer-term (1 week) 
dietary exposure. An ANOVA indicated that 
PFOA, PFPeA, and PB had no statistically 
significant effect on body weights of the rats 
(data not shown). Liver injury was assessed 
using the biomarkers sALT, sAST, sALP, and 
the results for both dosing schemes are pre-
sented in Table 1. At day 7, there were no 
significant differences between the rats treated 
with PFOA, PFPeA, and PB for all three of 
the selected liver enzymes, indicating no long-
term liver injury. After 1 day, we found a 
small, biologically insignificant, but statisti-
cally significant increase in sAST, with the 
data exhibiting high variability.
To assess the in vivo effects of these com-
pounds on GJIC in the liver tissue, we used an 
IL/DT technique. Figure 1A shows the incor-
poration of the fluorescent dye into the liver 
cells and subsequent distribution of the fluo-
rescent dye through the gap junctions of the 
tissue. RhD, which is a large-molecular-weight 
dye that does not traverse gap junctions, is 
color-coded red. LY, which does travel through 
gap junction channels, is color-coded from yel-
low for high intensity to green for lower inten-
sity. We measured and averaged the distances 
traveled by the gap-junction–permeable dye 
and show them in Figure 1B (acute exposure) 
and Figure 2 (long-term exposure). PFOA and 
PB but not PFPeA inhibited in vivo GJIC in 
the liver tissues of rats treated either acutely 
or chronically. Significant inhibition of GJIC 
by PFOA was observed after 1 hr, and contin-
ued to inhibit GJIC until 24 hr in the acutely 
treated rats. Significant inhibition of GJIC did 
not begin until after 12 hr of treatment with 
PB in this group of rats.
In the acute dose regimen (Figure 1C), a 
significant increase in the relative weight of liv-
ers from rats treated with PFOA was observed 
at 24 hr. Similarly, rats chronically exposed 
to PFOA and PB for 1 week had signifi-
cant increases in relative liver weight (RLW; 
Figure 2). The livers of animals treated either 
acutely or chronically with PFPeA did not sig-
nificantly increase in relative weights compared 
with rats fed the vehicle (Figures 1C, 2).
In vitro results. Considering that the 
in vitro results of PFOA and PFPeA effects 
on gap junctions correlated with their effects 
on gap junctions in vivo, we did further 
in vitro analyses of PFOA to determine under-
lying mechanisms involved in the dysregula-
tion of GJIC. PFOA, which inhibits GJIC, 
also activated ERK as determined by Western 
blot analysis of the phosphorylated, activated 
form of ERK (Figure 3). In contrast, the non-
GJIC inhibitory PFPeA did not activate ERK 
(Figure 3). Activation of ERK was within 
5 min in cells treated with PFOA, which cor-
relates with the time of inhibition of GJIC, 
indicating a potential link. Preincubation of 
the cells with an MEK inhibitor, U0126, par-
tially but significantly prevented the inhibition 
of GJIC by PFOA (Figure 4A). Preincubation 
of the cells with the PC-PLC inhibitor D609 
also partially but significantly prevented the 
inhibition of GJIC by PFOA (Figure 4A). The 
significant contribution of PC-PLC and MEK 
in PFOA-induced inhibition of GJIC dimin-
ished after the maximum inhibitory dose of 
80 µM to a nonsignificant involvement at the 
higher dose of 120 µM (Figure 4A), indicating 
further that mechanisms other than MEK and 
PC-PLC are also involved.
Gap junctions are known to be redox sen-
sitive, so we conducted several experiments 
with various antioxidants. Resveratrol signifi-
cantly reversed the inhibitory effect on GJIC 
and was possibly inhibiting both MEK and 
PC-PLC (Figure 4A). Additional experiments 
were performed to look at the combinatorial 
effect of pretreating cells with both D609 and 
U0126. The combination of both of these 
inhibitors of signal transduction enzymes 
resulted in the prevention of GJIC inhibi-
tion by PFOA, and the combinatorial effect 
was significantly greater than cells treated 
with either inhibitor alone as determined by 
a Tukey post hoc multiple-comparison test 
(Figure 4B). These results collectively indicate 
that PFOA-induced regulation of GJIC is a 
function of both of these signaling enzymes.
Further experiments were performed with 
DTT, Nac, and Asc-2-P (Figure 5). DTT 
Table 1. The effect of PFOA, PFPeA, and PB on the levels of various biomarkers of liver injury in F344 rats. 
  Enzyme activity (mU/mL)
Exposure, time, enzyme  DMSO (vehicle)  PFOA  PFPeA  PB
Acute (24 hr)       
  sALT  51.5 ± 3.2  138.6 ± 126.4  56.3 ± 13.2  54.5 ± 4.1
  sAST  98.8 ± 8.8  232 ± 169.8*  113.0 ± 17.6  100.6 ± 15.1
  sALP  1672.8 ± 90.0  1521.8 ± 220.2  1495.0 ± 233.8  1561.0 ± 115.2
Longer-term (1 week)       
  sALT  39.3 ± 2.0  41.2 ± 1.9  39.8 ± 3.0  39.7 ± 2.6
  sAST  71.2 ± 10.0  70.4 ± 4.3  73.9 ± 10.7  76.1 ± 9.4
  sALP  1488.8 ± 62.9  1394.5 ± 59.4  1449.5 ± 36.6  1349.3 ± 53.0
To determine significant effects, we performed a one-way ANOVA for sALP (1 day), sALP (1 week), and sALT (1 week) 
and a Kruskal-Wallis one-way ANOVA on ranks for sAST (1 day), sAST (1 week), and sALT (1 day). Any significant effects 
determined by ANOVA were followed by a Dunnett’s post hoc test, with DMSO designated as the control. 
*p < 0.05.
Figure 5. Prevention of PFOA-induced inhibition of 
GJIC by various antioxidants (mean + SD). The con-
centrations of PFOA, DTT, Nac, and Asc-2-P were 
80 µM, 10 mM, 100 µM, and 100 µM, respectively. 
*p < 0.05 by ANOVA and Dunnett’s post hoc test comparing 
each antioxidant treatment with that of PFOA alone (no 
antioxidant).
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and Nac in the absence of PFOA had no sta-
tistically (ANOVA) significant effect on GJIC 
at both 15 and 60 min (data not shown). 
Asc-2-P had a small, < 10% effect (ANOVA, 
Tukey) on GJIC in the absence of PFOA at 
15 min but not 60 min (data not shown). 
Asc-2-P and Nac both prevented the inhibi-
tion of GJIC by PFOA within a 60-min pre-
incubation time, but not DTT, implicating 
redox-sensitive proteins that probably do not 
involve thiol oxidations. Preincubation of Asc-
2-P and Nac for 15 min did not reverse the 
effect of PFOA on GJIC. The oxidative nature 
of PFOA was not cytotoxic, as indicated after 
2 days of growing cells after the log-phase of 
growth with 80 µM PFOA, resulting in no 
visual abnormalities in the morphology of the 
cells and complete restoration of GJIC after 
the cells were transferred to fresh medium for 
5 hr containing no PFOA (Figure 6).
Discussion
Understanding the biological effects of the 
environmentally prevalent PFFAs on cell sig-
naling pathways relevant to the epigenetic, 
nongenotoxic phase of cancer is important. In 
particular, GJIC offers a very central signal-
ing system to assess risk (Trosko and Upham 
2005). Although the transient closure of gap 
junction channels during proliferation is a 
normal response to mitogens, the chronic 
inhibition of GJIC by toxicants and toxins 
or by cytokines released during compensa-
tory hyperplasia could lead to pathologic 
states (Trosko and Upham 2005; Upham and 
Trosko 2006). Thus, we conducted two dos-
ing schemes, one a short term of 24 hr fol-
lowing an i.p. injection of PFOA, PFPeA, or 
PB, and another a longer-term study where 
the rats were dosed with these compounds 
through their daily feedings for 1 week. We 
previously demonstrated that inhibition of 
GJIC using in vitro model systems by perfluo-
roalkyl carboxylates and sulfonates depended 
on the chain length, where PFFAs with 7–10 
carbons inhibited GJIC, and PFFAs with 2–6 
carbons did not (Hu et al. 2002; Upham et al. 
1998). To determine if chain length of PFFAs 
would exhibit similar effects on GJIC in a 
living organism, we treated F344 rats with 
PFOA, an eight-carbon PFFA, and PFPeA, a 
five-carbon PFFA, and determined GJIC in 
the liver tissue using an ex vivo IL/DT assay.
The liver is the primary target of PFOA 
(Kudo and Kawashima 2003), which is 
known to induce hepatocellular tumors in 
rodent model systems (Abdellatif et al. 1991; 
Kennedy et al. 2004). Similar to our in vitro 
results (Hu et al. 2002; Upham et al. 1998), 
PFOA decreased GJIC activity in the liver 
compared with the rats treated with the 
vehicle (control) for both the acute and long-
term dosing schemes. In contrast, PFPeA-
treated rats did not have altered GJIC in 
the livers compared with the control rats for 
both dosing schemes, which is also consis-
tent with our in vitro observations. Another 
possible reason for the lack of an in vivo 
response by PFPeA could be a consequence 
of a greater elimination rate that is typical 
of PFFAs with shorter chain lengths (Chang 
et al. 2008; Ohmori et al. 2003). Although 
we did not measure the elimination rates of 
PFPeA in our experiments, the half-life of 
perfluorobutyrate is 9.2 hr (oral) and 6.4 hr 
(intravenous) in Sprague-Dawley rats (Chang 
et al. 2008). These half-lives are similar to 
that of PB in Sprague-Dawley rats, which is 
8–9 hr. Considering that PB inhibited GJIC 
and induced hepatomegaly in the livers of the 
rats used in our experiments, and PFPeA did 
not inhibit GJIC using an in vitro assay sys-
tem, we would expect that the noninhibitory 
effects of PFPeA on GJIC in vivo would not 
result from its increased rate of elimination. 
Further experiments are needed to confirm 
such a conclusion.
We previously published data that indi-
cated the treatment of Sprague-Dawley rats 
with PFOS resulted in a decrease in GJIC 
activity in the liver tissue; thus, PFOA and 
PFOS have similar activities (Hu et al. 2002). 
The following are additional reports dem-
onstrating that tumor promoters, known to 
inhibit GJIC in vitro, also inhibited GJIC 
in vivo: pentachlorophenol (Sai et al. 2000), 
2-acetylaminofluorene (Krutovskikh et al. 
1991), PB (Kolaja et al. 2000; Krutovskikh 
1995), polychlorinated biphenyls (Kolaja et al. 
2000; Krutovskikh 1995), pregnenolone-16α-
carbonitrile (Kolaja et al. 2000), cadmium 
(Jeong et al. 2000), clofibrate, and DDT 
(Krutovskikh 1995). Another interesting 
report on the in vivo effects of chemicals on 
GJIC is the treatment of rats with the antioxi-
dants lycopene and alpha and beta carotene. 
High doses of these antioxidants resulted 
in a decrease in GJIC activity, whereas rats 
exposed to low doses exhibited an increase 
in GJIC (Krutovskikh et al. 1997). Although 
in vivo assessment of intercellular communi-
cation has been limited in both the number of 
studies and choice of organ, namely, the liver, 
these results, including those presented in this 
report, nevertheless suggest that the in vitro 
rat liver epithelial cell assay system is a good 
predictor of the in vivo effects of chemicals on 
gap junctions in the liver tissues of rodents.
PFOA and PB induced hepatomegaly, 
whereas PFPeA had no effect. These results 
are similar to those previously published indi-
cating that PFOA, but not perfluorobutyrate, 
affected RLWs in F344 rats (Takagi et al. 
1991). Although not causally linked, hepato-
megaly has been correlated with the promo-
tion of liver tumors by many peroxisome 
proliferator-activated receptor α agonists, 
including PFOA (Takagi et al. 1992). The 
null effect of PFPeA on GJIC and hepato-
megaly suggest that PFPeA would not be a 
tumor promoter; however, two-stage (initia-
tion and promotion) carcinogenesis studies 
would be needed to confirm this conclusion. 
Tissue necrosis is known to induce com-
pensatory hyperplasia that leads to increased 
liver weights, but this is unlikely the cause of 
hepatomegaly in the PFOA- and PB-treated 
rats, considering that no visual damage of 
the liver was seen in the histologic sections 
(data not shown) and there was no increase in 
serum enzymes.
Tissue homeostasis in multicellular organ-
isms depends on functional GJIC, and the 
disruption of intercellular communication 
has been linked to many diseases (Trosko 
and Upham 2005). PFOA clearly interrupted 
GJIC in the liver tissues of rats, but further 
experiments would need to be done in other 
species. PFOS also inhibited GJIC in rat liver 
tissue as well as in vitro systems that included 
dolphin kidney cells (Hu et al. 2002). Thus, 
the potential for cross-species effects of PFOA 
on GJIC implicates a health risk to multi-
cellular organisms. Future experiments, par-
ticularly with human cell lines, will aid in 
determining differences in the sensitivity of 
various organisms to the effects of PFOS and 
PFOA on GJIC and allow for more accurate 
assessment of risks these compounds pose to 
humans and wildlife.
Considering that in vitro analyses of 
PFFA, using rat liver epithelial cells, accu-
rately predicted the in vivo effects on GJIC for 
various PFFAs, we did further in vitro anal-
yses of PFPeA- and PFOA-treated rat liver 
epithelial cells to determine potential signal-
ing mechanisms involved in PFOA-induced 
regulation of GJIC. Connexin 43 (Cx43) is a 
Figure 6. The effects of an extended incubation 
of cells with PFOA (80 µM, 2 days) and transfer of 
cells to PFOA-free medium (5 hr) on cell morphol-
ogy and GJIC (mean + SD). Each phase-contrast 
and fluorescent photomicrograph represents one 
of the three replicates of each treatment group 
(magnification, 200×). Different letters indicate 
significance at p < 0.05 using ANOVA and Tukey 
post hoc test with a pairwise comparison.
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phosphoprotein, and the phosphorylation of 
the carboxy terminus by protein kinases, such 
as protein kinase C (PKC), Src, and MAPKs, 
in the regulation of GJIC has been well docu-
mented (Solan and Lampe 2005). Although 
phosphorylation of gap junctions is known to 
regulate the function, assembly, internaliza-
tion, and degradation of this protein complex, 
the alteration of connexin phosphorylation 
by protein kinases, such as MAPKs, does not 
necessarily dysregulate gap junction function 
(Hossain et al. 1999), nor does the activa-
tion of protein kinases (i.e., MAPK) alter the 
phosphorylation status of connexins (Upham 
et al. 2008).
This was also true for PFOA, which clearly 
activated ERK-MAPK (Figure 3) but did not 
induce a change in the phosphorylation pat-
tern of Cx43 as previously determined by 
Western blot analysis (Upham et al. 1998). 
Whether or not gap junctions are phosphory-
lated, several compounds (i.e., growth factors, 
lindane, lysophosphatidic acid, 12-O-tetra-
decanoylphorbol-13-acetate, and cannabi-
noids) are known to inhibit GJIC through 
a MEK-dependent pathway (Komatsu et al. 
2006; Mograbi et al. 2003; Rivedal and 
Opsahl 2001; Upham et al. 2003). Although 
many compounds activate MAPKs, such as 
p38 and ERK, the mechanism of inhibiting 
GJIC by many of these compounds is inde-
pendent from these MAPKs (Machala et al. 
2003; Upham et al. 2008).
Our results indicated that PFOA acti-
vated ERK in F344 WB rat liver epithelial 
cells within 5 min, and this time period is 
within the interval required for the inhibition 
of GJIC by PFOA in this cell line. PFPeA, 
which does not inhibit GJIC in this cell line 
(Upham et al. 1998), also did not activate 
ERK. Preincubation of these cells with an 
MEK inhibitor, U0126, partially prevented 
PFOA from inhibiting GJIC, indicating that 
PFOA-induced modulation of GJIC was not 
solely dependent on the ERK pathway.
Recently, PC-PLC has been implicated 
in the dysregulation of GJIC in response to 
toxicants that regulate GJIC through an MEK-
independent mechanism (Machala et al. 2003; 
Upham et al. 2008). Preincubation of F344 
WB cells with the PC-PLC inhibitor D609 
also partially prevented PFOA from inhibit-
ing GJIC. These results suggest that PFOA 
is regulating GJIC through multiple cellu-
lar mechanisms. This becomes more appar-
ent as the dose of PFOA is increased resulting 
in the inhibition of GJIC at a high dose of 
120 µM that depended on neither PC-PLC 
nor MEK. However, maximum inhibition of 
GJIC by PFOA, which was around 80 µM, 
was very dependent on the activity of both 
MEK and PC-PLC. This was further appar-
ent from the experiment where cells were pre-
treated with a combination of both D609 and 
U0126, resulting in almost complete recovery 
of GJIC. The activation of ERK and PC-PLC 
will not only control gap junction function 
but is known to alter gene expression, leading 
to various pathologies, including cancer. The 
function of PC-PLC in tumorigenesis has not 
been extensively studied, yet there are signifi-
cant reports indicating that PC-PLC does play 
a very significant role in cancer (Cheng et al. 
1997). The ERK pathway has been extensively 
characterized and is the most understood of 
the MAPK pathways (Denhardt 1996) and is 
a key pathway of carcinogenesis (Roberts and 
Der 2007).
PFOA, but not perfluorobutyrate, is 
known to induce oxidative stress in the liv-
ers of rats, as indicated by 8-hydroxydeoxy- 
guanosine formation (Takagi et al. 1991), and 
redox mechanisms are known to commonly 
play a role in gap junction function (Upham 
and Trosko 2009). These oxidative signaling 
effects could be site-directed redox regulations 
of specific regulatory proteins or from general 
oxidative effects (Upham and Trosko 2008). 
Recently, we reported that the antioxidant 
resveratrol prevented inhibition of GJIC by 
dicumylperoxide but not by benzoylperoxide 
(Upham et al. 2007). Dicumylperoxide, but 
not benzoylperoxide, inhibits GJIC through 
a PC-PLC–dependent mechanism (Upham 
et al. 2007). Similar to dicumylperoxide, we 
showed that resveratrol prevented inhibi-
tion of GJIC by PFOA to a greater level than 
either D609 or U0126 alone, but similar to 
the level of GJIC recovery seen when cells 
were pretreated with both D609 and U0126. 
These results indicate the possibility that 
PFOA dysregulates GJIC through both MEK 
and PC-PLC and that protection of GJIC 
by resveratrol is potentially through oxidative 
signaling events controlling both MEK and 
PC-PLC. Beyond the implication of redox 
mechanisms of the resveratrol experiment, this 
antioxidant is regularly consumed by humans 
and is found in high concentrations in red 
wine and peanut products (Sobolev and Cole 
1999; Wang et al. 2002), and thus may have 
some relevance to the health of humans that 
may be exposed to environmental toxicants, 
such as PFOA. Chemopreventive effects of 
resveratrol are known to inhibit initiation, pro-
motion, and progression of tumors (Signorelli 
and Ghidoni 2005). Thus, resveratrol could 
potentially contribute to a protective effect 
in humans exposed to PFOA by significantly 
blocking PFOA from inhibiting GJIC.
The addition of Asc-2-P or Nac partially 
reversed the inhibitory effects of PFOA on 
GJIC, similar to that of resveratrol. In con-
trast, DTT did not prevent PFOA from 
inhibiting GJIC, indicating that the oxidative 
events controlling PC-PLC and Mek are not 
thiol based. The exposure of F344 WB cells 
to PFOA for 2 days showed no adverse effects 
on cell morphology, and they communicated 
normally after PFOA was removed from the 
medium (Figure 6), which implicates that the 
PFOA-induced oxidative events are not kill-
ing the cells. These results suggest that general 
oxidative processes are involved in PFOA-
induced inhibition of GJIC and that health 
benefits could potentially be attained by the 
consumption of many antioxidant rich foods, 
particularly in individuals deficient in antioxi-
dants. Moreover, the reversible properties of 
PFOA-induced inhibition of GJIC are con-
sistent with the known reversible nature of 
tumor promoters in two-stage carcinogenesis 
model systems (Trosko and Upham 2005). 
These results also indicate that reversing the 
effect of PFOA on GJIC after a simple wash-
ing of the treated cells with PBS demonstrates 
that PFOA is not covalently or tightly bound 
to the cell. The effect of PFOA on GJIC was 
probably not a consequence of directly inter-
acting with the gap junction proteins because 
the inhibition of MAPK and PC-PLC both 
prevented the GJIC effect. Possibly PFOA 
interacted with these two proteins or inter-
acted with a signaling protein or receptor even 
further upstream.
In conclusion, the in vitro assay system 
used to assess the effects of PFOA and PFPeA 
on GJIC predicted the in vivo results of GJIC 
from rats treated with these compounds. GJIC 
plays a vital role in maintaining tissue homeo-
stasis, and disruption of gap junction function 
can lead to diseased states such as tumorigen-
esis. These results are similar to other tumor-
promoting compounds tested in both an 
in vitro and in vivo assay system. Although 
there are several mechanisms by which envi-
ronmental compounds might promote an 
initiated cell, such as through peroxisome pro-
liferator activated receptors or protein kinase 
C, the disruption of normal intercellular com-
munication is an essential event of multiple 
tumorigenic mechanisms (Trosko and Upham 
2005) and serves as a central biomarker to 
assess the epigenetic toxicity of contaminants 
(Rosenkranz et al. 1997; Trosko and Upham 
2005), as well as to assess the potential anti-
tumorigenic health benefits of nutrition based 
food products (Trosko and Upham 2005).
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